This website is intended for healthcare professionals

close-icon

Log In to Bolder Science

or

Don't have an account? Sign Up

close-icon

Please enter your email address.

You will receive a link to create a new password via email.

Log In

close-icon

Create an Account

or
  • 8 characters minimum
  • First character may not be a number
  • Last character may not be a number
close-icon

Welcome and thank you for creating an account!

At Bolder Science, we want your clinical trial search experience to be the best it can be. Complete the following prompts to easily find the trials you are interested in and see trials recruiting near you. You can adjust these selections in your dashboard after creating your account.

Condition Categories

Condition categories are pulled directly from ClinicalTrials.gov. Choose 1 or more condition categories that you are interested in:

Clinical Trials of Interest

When I’m looking for information on clinical trials, I usually am interested in...

Set a default location

ACTIV-2: A Study for Outpatients With COVID-19

  • Clinicaltrials.gov identifier

    NCT04518410

  • Recruitment Status

    Recruiting

  • First Posted

    August 19, 2020

  • Last update posted

    December 17, 2021

Study Description

Brief summary:

Drug studies often look at the effect one or two drugs have on a medical condition, and involve one company. There is currently an urgent need for one study to efficiently test multiple drugs from more than one company, in people who have tested positive for COVID-19 but who do not currently need hospitalization. This could help prevent disease progression to more serious symptoms and complications, and spread of COVID-19 in the community. This study looks at the safety and effectiveness of different drugs in treating COVID-19 in outpatients. In Phase II, participants in the study will be treated with either a study drug or with placebo. In protocol version 7.0, participants in Phase III of the study will be treated with either a study drug or active comparator drug. Participants assigned to the bamlanivimab agent/placebo arm and will have 28 days of intensive follow-up following study drug administration, followed by limited follow-up through 24 weeks in phase II and in phase III. All other investigational agents and their corresponding placebo arms will involve 28 days of intensive follow-up, followed by limited follow-up through 72 weeks in phase II and phase III. Additional study visits may be required, depending on the agent.

  • Condition or Disease:Coronavirus
    Covid19
  • Intervention/Treatment: Biological: bamlanivimab
    Drug: Placebo (IV)
    Biological: BRII-196/BRII-198
    Biological: AZD7442 (IV)
    Biological: AZD7442 (IM)
    Drug: SNG001
    Drug: Camostat
    Drug: Placebo (IM)
    Drug: Placebo (Inhaled solution)
    Drug: Placebo (oral tablet)
    Biological: BMS-986414 + BMS-986413
    Drug: Placebo (SC injections)
    Biological: SAB-185 (3,840 Units/kg)
    Biological: SAB-185 (10,240 Units/kg)
    Drug: CASIRIVIMAB + IMDEVIMAB
  • Phase: Phase 2/Phase 3

Detailed Description

This is a master protocol to evaluate the safety and efficacy of multiple investigational agents aimed at modifying the host immune response to SARS-CoV-2 infection, or directly enhancing viral control in order to limit disease progression. The study includes both infused and non-infused agents and is a randomized controlled platform that allows agents to be added and dropped during the course of the study for efficient phase II and phase III testing of new agents within the same trial infrastructure. Version 7 of the protocol provided for blinded phase II evaluation of an investigational agent for superiority to placebo among participants at lower risk of progression to hospitalization or death, regardless of the mode of administration of the agent. Agents that graduate to phase III after initiation of the protocol version will be evaluated in persons at higher risk for progression to hospitalization or death for non-inferiority to an active comparator (monocolonal antibody cocktail of casirivimab plus imdevimab (REGEN-COV, Regeneron). This active comparator has been shown to be effective in this population in preventing hospitalization or death. When two or more agents are being evaluated in the same phase of the study, the trial design includes sharing of the control group (placebo in phase II and active comparator in phase III) for efficient evaluation of each agent. Investigational agents will be approved by the Trial Oversight Committee (TOC) for phase II evaluation based on the presence of in vitro data demonstrating promise as anti-SARS-CoV-2 therapeutics in pre-clinical testing, and for which there are suitable pharmacokinetics and safety data from phase I testing, or through clinical or research testing for a different indication, and agent availability. Investigational agents will be included in phase III evaluation based on agent entry criteria for phase III as outlined in the protocol (or by TOC approval based on data available outside ACTIV-2).

Study Design

  • Study Type: Interventional
  • Estimated Enrollment: 8797 participants
  • Allocation: Randomized
  • Intervention Model: Parallel Assignment
  • Masking: Triple (Participant, Care Provider, Investigator)
  • Primary Purpose: Treatment
  • Official Title: Adaptive Platform Treatment Trial for Outpatients With COVID-19 (Adapt Out COVID)
  • Actual Study Start Date: August 2020
  • Estimated Primary Completion Date: December 2023
  • Estimated Study Completion Date: December 2023

Arms and interventions

Arm Intervention/treatment
Experimental: Bamlanivimab
Administered by IV infusion.
Biological: bamlanivimab
7000 mg or 700 mg (Phase 2), 700 mg (Phase 3). Administered by single IV infusion. Phases 2 and 3 completed for bamlanivimab. Participants are no longer being randomized to this intervention.
Experimental: Placebo (IV)
The placebo arm may be pooled across more than one experimental arm if multiple investigational drug are available to be tested at the same time and use the same method of administration. If it is not possible to use matching placebo over more than one experimental arm, additional placebo arms will be included in the study
Drug: Placebo (IV)
Commercially available 0.9% sodium chloride solution.
Experimental: BRII-196/BRII-198
Administered by IV infusion.
Biological: BRII-196/BRII-198
1000 mg (BRII-196)/1000 mg (BRII-198) combination therapy. Administered by consecutive IV infusions as single dose. Participants are no longer being randomized to this intervention.
Experimental: AZD7442 (IV)
Administered by IV infusion.
Biological: AZD7442 (IV)
300 mg AZD7442 (150 mg AZD8895 + 150 mg AZD1061). Administered by IV infusion as single dose. Participants are no longer being randomized to this intervention.
Experimental: AZD7442 (IM)
Administered by IM injection.
Biological: AZD7442 (IM)
Administered intramuscularly as 2 separate injections sequentially (300 mg AZD8895 then 300 mg AZD1061) for one dose. Injections administered in the side of the thigh, one injection in each thigh. Participants are no longer being randomized to this intervention.
Experimental: SNG001
Administered by inhalation.
Drug: SNG001
1.3 mL solution administered once daily for 14 days using Aerogen Ultra nebulizer (inhalation device).
Experimental: Camostat
Administered as oral tablets.
Drug: Camostat
200 mg (2 x 100 mg) film-coated tablets administered orally every 6 hours for 7 days. Participants are no longer being randomized to this intervention.
Placebo Comparator: Placebo (IM)
The placebo arm may be pooled across more than one experimental arm if multiple investigational drug are available to be tested at the same time and administered in the same way. If it is not possible to use matching placebo over more than one experimental arm, additional placebo arms will be included in the study
Drug: Placebo (IM)
Commercially available 0.9% sodium chloride Injection, USP. Administered intramuscularly as 2 separate injections, sequentially for one dose. Injections administered in the side of the thigh, one injection in each thigh.
Placebo Comparator: Placebo (Inhaled solution)
The placebo arm may be pooled across more than one experimental arm if multiple investigational drug are available to be tested at the same time and administered in the same way. If it is not possible to use matching placebo over more than one experimental arm, additional placebo arms will be included in the study
Drug: Placebo (Inhaled solution)
Trisodium citrate dihydrate, di-sodium hydrogen-phosphate, sodium dihydrogen-phosphate dihydrate, racemic methionine (DL-methionine) and water. 1.3 mL solution administered once daily for 14 days using Aerogen Ultra nebulizer (inhalation device).
Placebo Comparator: Placebo (oral tablets)
The placebo arm may be pooled across more than one experimental arm if multiple investigational drug are available to be tested at the same time and administered in the same way. If it is not possible to use matching placebo over more than one experimental arm, additional placebo arms will be included in the study
Drug: Placebo (oral tablet)
200 mg (2 x 100 mg) film-coated tablets administered orally every 6 hours for 7 days.
Experimental: BMS 986414 + BMS 986413
Administered as subcutaneous (SC) injections.
Biological: BMS-986414 + BMS-986413
Administered subcutaneously (SC) as 4 separate injections for one dose (two injections of C135-LS 200mg and two injections of C144-SL 200mg).
Placebo Comparator: Placebo (SC injections)
The placebo arm may be pooled across more than one experimental arm if multiple investigational drug are available to be tested at the same time and administered in the same way. If it is not possible to use matching placebo over more than one experimental arm, additional placebo arms will be included in the study
Drug: Placebo (SC injections)
Administered SC as 4 separate injections for one dose.
Experimental: SAB-185 (Lower dose)
Administered by IV infusion.
Biological: SAB-185 (3,840 Units/kg)
Administered by IV infusion as single dose.
Experimental: SAB-185 (Higher dose)
Administered by IV infusion.
Biological: SAB-185 (10,240 Units/kg)
Administered by IV infusion as single dose.
Active Comparator: Casirivimab + Imdevimab (Phase III only)
Administered by IV infusion
Drug: CASIRIVIMAB + IMDEVIMAB
600 mg casirivimab and 600 mg imdevimab, administered together as single IV infusion as one-time dose at study entry.

Outcome Measures

  • Primary Outcome Measures: 1. COVID-19 symptom duration (Phase 2) [ Time Frame: Up to Day 28 ]
    Duration defined as the number of days from start of investigational agent to the first of two consecutive days when any symptoms scored as moderate or severe as study entry (pre-treatment) are scored as mild or absent; and any symptoms scored as mild or absent at study entry are scored as absent, AND any symptoms scored as mile or absent at study entry (pre-treatment) are scored as absent. Targeted symptoms are: Feeling feverish; cough, shortness of breath or difficulty breathing; sore throat; body pain or muscle pain/aches; fatigue (low energy); headache, chills, nasal obstruction or congestion (stuffy nose); nasal discharge (runny nose); nausea or vomiting; and diarrhea. Each symptom is scored daily by the participant as absent (score 0), mild (1), moderate (2) or severe (3)
  • 2. Quantification of SARS-CoV-2 RNA (Phase 2) [ Time Frame: Day 3 ]
    Measured as quantification (<LLoQ versus ≥LLoQ ) from staff-collected NP (nasopharyngeal) swabs
  • 3. Quantification of SARS-CoV-2 RNA (Phase 2) [ Time Frame: Day 7 ]
    Measured as quantification (<LLoQ versus ≥LLoQ ) from staff-collected NP (nasopharyngeal) swabs
  • 4. Quantification of SARS-CoV-2 RNA (Phase 2) [ Time Frame: Day 14 ]
    Measured as quantification (<LLoQ versus ≥LLoQ ) from staff-collected NP (nasopharyngeal) swabs
  • 5. Proportion of participants with new adverse event (AE) ≥ Grade 3 (Phase 2) [ Time Frame: Thru Day 28 ]
  • 6. Cumulative incidence of death due to any cause or hospitalization due to any cause (Phase 3) [ Time Frame: Thru Day 28 ]
    Hospitalization defined as ≥24 hours of acute care in a hospital or similar acute care facility, including Emergency Rooms or temporary facilities instituted to address medical needs of those with severe COVID-19
  • 7. Proportion of participants with new adverse event (AE) ≥ Grade 3 (Phase 3) [ Time Frame: Thru Day 28 ]
  • Secondary Outcome Measures: 1. COVID-19 symptom duration (Phase 3) [ Time Frame: Thru Day 28 ]
    Duration defined as the number of days from start of investigational agent to the first of two consecutive days when any symptoms scored as moderate or severe as study entry (pre-treatment) are scored as mild or absent; and any symptoms scored as mild or absent at study entry are scored as absent, AND any symptoms scored as mile or absent at study entry (pre-treatment) are scored as absent. Targeted symptoms are: Feeling feverish; cough, shortness of breath or difficulty breathing; sore throat; body pain or muscle pain/aches; fatigue (low energy); headache, chills, nasal obstruction or congestion (stuffy nose); nasal discharge (runny nose); nausea or vomiting; and diarrhea. Each symptom is scored daily by the participant as absent (score 0), mild (1), moderate (2) or severe (3)
  • 2. Quantification of SARS-CoV-2 RNA (Phase 3) [ Time Frame: Day 3 ]
    Measured as quantification (<LLoQ versus ≥LLoQ ) from staff-collected NP (nasopharyngeal) swabs
  • 3. Cumulative incidence of death from any cause or hospitalization due to any cause (Phase 2) [ Time Frame: Thru Day 28 ]
    Hospitalization defined as ≥24 hours of acute care in a hospital or similar acute care facility, including Emergency Rooms or temporary facilities instituted to address medical needs of those with severe COVID-19
  • 4. Cumulative incidence of death from any cause, or hospitalization due to any cause related to COVID-19 (Phase 3) [ Time Frame: Thru Day 28 ]
    Hospitalizations due to any cause deemed unrelated to COVID-19 are excluded. Hospitalization defined as ≥24 hours of acute care in a hospital or similar acute care facility, including Emergency Rooms or temporary facilities instituted to address medical needs of those with severe COVID-19
  • 5. Level of SARS-CoV-2 RNA from NP swabs (Phase 2) [ Time Frame: Thru Day 14 ]
    Measured from staff-collected NP swabs
  • 6. Level of SARS-CoV-2 RNA from NP swabs (Phase 3) [ Time Frame: Day 3 ]
    Measured from staff-collected NP swabs
  • 7. Duration of targeted clinical COVID-19 symptoms (Phases 2 and 3) [ Time Frame: Thru Day 28 ]
    Duration defined as the number of days from start of investigational agent to the first of four consecutive days when all symptoms scored as absent. Targeted symptoms are: Feeling feverish; cough, shortness of breath or difficulty breathing; sore throat; body pain or muscle pain/aches; fatigue (low energy); headache, chills, nasal obstruction or congestion (stuffy nose); nasal discharge (runny nose); nausea or vomiting; and diarrhea. Each symptom is scored daily by the participant as absent (score 0), mild (1), moderate (2) or severe (3)
  • 8. COVID-19 symptom severity ranking (Phases 2 and 3) [ Time Frame: From Day 0 thru Day 28 ]
    Based on symptom severity scores. Symptoms: Fever or feeling feverish; cough, shortness of breath or difficulty breathing at rest or with activity; sore throat; body pain or muscle pain/aches; fatigue; headache, chills, nasal obstruction or congestion; nasal discharge (runny nose); nausea or vomiting; and diarrhea. Each symptom is scored daily by the participant as absent (score 0), mild (1), moderate (2) or severe (3). For participants who are alive at 28 days and not previously hospitalized, the severity ranking will be based on the area under the curve (AUC) of the symptom score associated with COVID-19 disease over time. Participants hospitalized or who die during follow-up through 28 days will be ranked as worse than those alive and never hospitalized as follows (in worsening rank order): alive and not hospitalized at 28 days; hospitalized but alive at 28 days; and died at or before 28 days.
  • 9. Proportion of participants with ≥1 worsening symptom of COVID-19 (Phases 2 and 3) [ Time Frame: Thru Day 28 ]
    Progression of one or more COVID-19-associated symptoms to a worse status than recorded in study diary at study entry, prior to start of investigational product or placebo
  • 10. Time to self-reported return to usual health (a) (Phases 2 and 3) [ Time Frame: Thru Day 28 ]
    Defined as the number of days from start of investigational treatment until the first of two consecutive days that a participant reported return to usual (pre-COVID-19) health as recorded in a participant's study diary
  • 11. Cumulative incidence of death due to any cause or hospitalization due to any cause (Phases 2 and 3) [ Time Frame: Day 0 thru Week 24 ]
  • 12. Cumulative incidence of death due to any cause or hospitalization due to any cause (Phases 2 and 3) [ Time Frame: Day 0 thru Week 72 ]
  • 13. Oxygen saturation level (Phase 2) [ Time Frame: Thru Day 28 ]
    Measured by pulse oximeter and categorized as <96% versus ≥96%
  • 14. AUC of SARS-CoV-2 RNA from site-collected NP swabs (Phase 2) [ Time Frame: Thru Day 14 ]
    Measured by area under the curve (AUC) and above assay lower limit of quantification of quantitative SARS-CoV-2 RNA over time
  • 15. Incidence of new adverse event (AE) ≥ Grade 2 (Phases 2 and 3) [ Time Frame: Thru Day 28 ]
  • 16. Incidence of new adverse event (AE) ≥ Grade 2 (Phases 2 and 3) [ Time Frame: Thru Week 24 ]
  • 17. Incidence of new adverse event (AE) ≥ Grade 3 (Phases 2 and 3) [ Time Frame: Thru Week 24 ]
  • 18. Time to self-reported return to usual health (b) (Phases 2 and 3) [ Time Frame: Thru Day 28 ]
    Defined as the number of days from start of investigational treatment until the first of four consecutive days that a participant reported return to usual (pre-COVID-19) health as recorded in a participant's study diary

Eligibility Criteria

  • Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
  • Sexes Eligible for Study: All
  • Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria: Signed informed consent. Documentation of laboratory-confirmed SARS-CoV-2 infection, as determined by a molecular (nucleic acid) or antigen test from any respiratory tract specimen (e.g. oropharyngeal, nasopharyngeal (NP), or nasal swab, or saliva) collected ≤240 hours (10 days) prior to study entry. Laboratory-confirmed SARS-CoV-2 infection outside the US must be conducted at a DAIDS-approved laboratory. Able to begin study treatment no later than 7 days from self-reported onset of COVID-19 related symptom(s) or measured fever, where the first day of symptoms is considered symptom day 0 and defined by the self-reported date of first reported sign/symptom from the following list: subjective fever or feeling feverish cough shortness of breath or difficulty breathing at rest or with activity sore throat body pain or muscle pain/aches fatigue headache chills nasal obstruction or congestion nasal discharge loss of taste or smell nausea or vomiting diarrhea temperature > 38°C (100.4°F) One or more of the following signs/symptoms within 24 hours of participating in the study: subjective fever or feeling feverish cough shortness of breath or difficulty breathing at rest or with activity sore throat body pain or muscle pain/aches fatigue headache chills nasal obstruction or congestion nasal discharge loss of taste or smell nausea or vomiting diarrhea temperature > 38°C (100.4°F) Oxygen levels of ≥92% obtained at rest (adjusted as needed for altitude) by study staff within 24 hours of study entry. For a potential participant who regularly receives chronic supplementary oxygen for an underlying lung condition, their oxygen saturation should be measured while on their standard home oxygen supplementation level. Participant must agree not to participate in another clinical trial for the treatment of COVID-19 or SARS-CoV-2 during the study period until hospitalization or 28 days after the start of the study, whichever occurs first. Meet the protocol definition of being at "higher" risk of progression to hospitalization or death (BRII-196/BRII-198). In Phase III, meeting the protocol definition of being at "higher" risk of progression to hospitalization or death (SNG001, SAB-185, BMS 986414+BMS 986413) For participants of reproductive potential, negative serum or urine pregnancy test within 48 hours prior to study entry by any clinic or laboratory that has a CLIA certification or its equivalent, or by a point of care (POC)/CLIA-waived test. Note: Participants not of reproductive potential are eligible without requiring the use of a contraceptive method (BRII-196/BRII-198. AZD7442 [IV], AZD7442 [IM], SNG001, Camostat, SAB-185, BMS 986414+BMS 986413). Participants that engage in sexual activity that may lead to pregnancy in their partner must agree to either remain abstinent or use male contraceptives. They are strongly advised to inform their non-pregnant sexual partners of reproductive potential to use effective contraceptives for 24 weeks after investigational product is administered. Participants with pregnant partners should use condoms during vaginal intercourse through 24 weeks after investigational agent administration. Participants should refrain from sperm donation for 24 weeks after investigational agent administration (BRII-196/BRII-198, AZD7442 [IV], AZD7442 [IM], SAB-185). Participants that engage in sexual activity that may lead to pregnancy in their partner must agree to either remain abstinent or use male contraceptives for 30 days after investigational agent administration. They are also strongly advised to inform their non-pregnant sexual partners of reproductive potential to sue effective contraceptives for 30 days after investigational agent is administered to the participant. Participants with pregnant partners should use condoms during vaginal intercourse through 30 days after last dose of investigational agent administration. Participants should refrain from sperm donation for 30 days after investigational agent administration (SNG001). Participants that engage in sexual activity that may lead to pregnancy in their partner must agree to either remain abstinent or use male contraceptives. They are also strongly advised to inform their non-regnant sexual partners of reproductive potential to use effective contraceptives from study entry through 90 days after study treatment. Participants with pregnant partners should use condoms during vaginal intercourse from study entry through 90 days after the last dose of the study treatment. Participants should refrain from sperm donation from study entry through 90 days after the last dose of study treatment (Camostat). If participating in sexual activity that could lead to pregnancy, participants who are of reproductive potential must agree to use effective contraception for 24 weeks after investigational agent is administered. This would include oral contraceptives, implanted contraceptives, implanted contraceptives, intrauterine devices, and barrier methods. If participating in sexual activity that could lead to pregnancy, participants who are of reproductive potential must agree to use highly effective contraception for 24 weeks after investigational agent is administered (AZD7442 [IV], AZD7442 [IM], SAB-185). If participating in sexual activity that could lead to pregnancy, participants who are of reproductive potential must agree to use effective contraception for 30 days after investigational agent is administered (SNG001). If participating in sexual activity that could lead to pregnancy, participants who are of reproductive potential must agree to use effective contraception for 90 days after the last dose of treatment (Camostat). If participating in sexual activity that could lead to pregnancy, participants who are of reproductive potential must agree to use highly effective contraception for at least 48 weeks after the investigational agent is administered (BMS 986414+BMS 986413). Exclusion Criteria: History of or current hospitalization for COVID-19. For the current SARS-CoV-2 infection, any positive SARS-CoV-2 nucleic acid or antigen tests from any respiratory tract specimen collected > 240 hours prior to study entry. Current need for hospitalization or immediate medical attention. Use of any prohibited medication listed in the protocol and/or use of systemic or inhaled steroids for the purpose of COVID-19 treatment (new or increased dose from chronic baseline) within 30 days prior to study. Receipt of convalescent COVID-19 plasma or other antibody-based anti-SARS-CoV-2 treatment or prophylaxis at any time prior to study entry. Receipt of other investigational treatments for SARS-CoV-2 any time before participating in the study (not including drugs approved and taken for other conditions/diseases or COVID-19 vaccines). Known allergy/sensitivity or hypersensitivity to study drug or placebo. Any condition requiring surgery up to 7 days before participating in the study, or that is considered life threatening up to 30 days before participating in the study. Currently pregnant or breastfeeding (BRII-196/BRII-198, AZD7442 [IV], AZD7442 [IM], SNG001, Camostat, SAB-185, BMS 986414+BMS 986413). In phase II, meeting the protocol definition of being at "higher" risk of progression to hospitalization or death (AZD7442 [IV], AZD7442 [IM], SNG001, Camostat, SAB-185, BMS 986414+BMS 986413). Inflammatory skin conditions that compromise the safety of intramuscular (IM) injections, or other overlying skin conditions or tattoos that would preclude the assessment of injection site reactions, per the discretion of the investigator (AZD7442 [IM]). Inflammatory skin conditions that compromise the safety of subcutaneous (SC) injections, or other overlying skin conditions or tattoos that would preclude the assessment of infection site reactions, per the discretion of the investigator (BMS 986414+BMS 986413). History of coagulopathy which, in the opinion of the investigator, would preclude IM injection, or use of oral or injectable anticoagulants (protocol provides more information on prohibited medications) (AZD7442 [IM]). Use of or need for chronic supplemental oxygen (SNG001). Known severe liver disease prior to enrollment (defined as ALT or AST > 5 times upper limit of normal or end stage liver disease with Child-Pugh Class C or Child-Pugh-Turcotte score ≥ 10) (Camostat). Known severe kidney disease prior to enrollment (defined as estimated glomerular filtration rate (eGFR) <30 ml/min/1.73m² or on renal-replacement therapy such as peritoneal dialysis or hemodialysis (Camostat) Other investigational drug protocol-defined inclusion/exclusion criteria may apply.

Contacts and Locations

Contacts

Locations

United States, Alabama
Pinnacle Research Group (Site 1082), 321 E. 10th Street
Anniston

United States, Alabama
North Alabama Research Center LLC (Site 1194), 721 W. Market St., Ste. B
Athens

United States, Alabama
University of Alabama at Birmingham (Site 1005), 908 20th Street South
Birmingham

United States, Alabama
Cullman Clinical Trials (Site 1140), 501 Clark St. NE.
Cullman

United States, Alabama
Jasper Summit Research, LLC. (Site 1056), 1280 Summit
Jasper

United States, Arizona
Absolute Clinical Research, LLC. (Site 1186), 7725 North 43rd Avenue, Ste. 211
Phoenix

United States, Arizona
University of Arizona (Site 1043), 1501 N. Campbell Ave., Rm. 6410
Tucson

United States, California
Omnibus Clinical Research (Site 1253), 3340 W. Ball Road, Ste. I
Anaheim

United States, California
Franco A. Felizarta MD (Site 1174), 3535 San Dimas St.
Bakersfield

United States, California
Clearview Medical Research LLC. (Site 1251), 2714 Hidaway Ave., Ste. 103
Canyon Country

United States, California
St. Jude Heritage Medical Group (Site 1093), 2151 N. Harbor Blvd.
Fullerton

United States, California
University of California San Diego (Site 1160), 9350 Campus Point Drive, Perlman Cancer Cancer
La Jolla

United States, California
Fadi A. Haddad, MD, Inc. (Site 1146), 8860 Center Dr., Ste. 320
La Mesa

United States, California
Atella Clinical Research (Site 1111), 5451 La Palma Avenue
La Palma

United States, California
Loma Linda University Health (Site 1110), 11374 Mountain View, Dover Bldg, Ste. C
Loma Linda

United States, California
University of Southern California (Site 1057), 1300 N. Mission Rd., Rm 349
Los Angeles

United States, California
UCLA CARE Center (Site 1003), 11075 Santa Monica Blvd., Suite 100
Los Angeles

United States, California
Science 37, Inc. (Site 1124), 12121 Bluff Creek Dr., Ste. 100
Los Angeles

United States, California
VA Northern California Health Care System (NAVREF) (Site 1137), 10535 Hospital Way
Mather

United States, California
Central Valley Research, LLC (Site 1085), 400 E. Orangeburg Ave., Ste. 5
Modesto

United States, California
Hoag Memorial Hospital Presbyterian (Site 1200), 1 Hoag Dr.
Newport Beach

United States, California
Valley Clinical Research, Inc. (Site 1059), 18433 Roscoe Blvd., Ste 210
Northridge

United States, California
University of California Irvine (Site 1083), 843 Health Sciences Road
Orange

United States, California
FOMAT Medical Research (Site 1136), 300 South A Street
Oxnard

United States, California
Eisenhower Medical Center (Site 1040), 39000 Bob Hope Drive
Rancho Mirage

United States, California
Paradigm Research (Site 1150), 3652 Eureka Way
Redding

United States, California
Riverside Medical Clinic (Site 1232), 7117 Brockton Ave.
Riverside

United States, California
University of California Davis Medical Center (Site 1097), 2315 Stockton Blvd.
Sacramento

United States, California
Premier Urgent Care Centers of California, Inc. (Site 1176), 284 E. Highland Ave.
San Bernardino

United States, California
University of California San Diego (Site 1002), 220 Dickinson Street
San Diego

United States, California
Zion Medical Center (Site 1063), 4647 Zion Avenue
San Diego

United States, California
VA San Diego Health System (Stie 1127), 3350 La Jolla
San Diego

United States, California
University of California San Francisco (Site 1009), 995 Potrero Ave., Building 80, Ward 84
San Francisco

United States, California
San Francisco Research Institute (Site 1210), 2435 Ocean Ave.
San Francisco

United States, California
Stanford University (Site 1213), 1201 Welch Road
Stanford

United States, California
Millennium Clinical Trials (Site 1260), 550 Saint Charles Dr., Ste. 208
Thousand Oaks

United States, California
Office of Ramesh V. Nathan, MD (Site 1073), 2220 Lynn Rd., Ste. 301
Thousand Oaks

United States, California
Harbor UCLA (Site 1022), 1124 West Carson Street
Torrance

United States, California
Allianz Research Institute Inc. (Site 1159), 14120 Beach Blvd., Ste. 101
Westminster

United States, Colorado
University of Colorado (Site 1007), 12401 East 17th Avenue
Aurora

United States, Connecticut
UConn - Institute for Collaboration on Health (Site 1169), 2006 Hillside Rd., Unit 1248
Storrs

United States, District of Columbia
Whitman-Walker Health (Site 1027), 1337 R Street NW.
Washington

United States, Florida
Imagine Research of Palm Beach County (Site 1157), 709 S. Federal Hwy., Ste. 2
Boynton Beach

United States, Florida
Bradenton Research Center Inc. (Site 1109), 3924 9th Ave. W
Bradenton

United States, Florida
Synergy Healthcare (Site 1099), 300 Riverside Drive E., Ste. 1350
Bradenton

United States, Florida
Cardiology Physicians, P.A. (Site 1180), 305 Memorial Medical Pkwy., Ste. 301
Daytona Beach

United States, Florida
Midland Florida Clinical Research Center LLC (Site 1130), 665 Peachwood Drive
DeLand

United States, Florida
Integrity Clinical Research (Site 1214), 3901 NW 79th Ave.
Doral

United States, Florida
Universal Axon Clinical Research (Site 1077), 3650 NW 82nd Ave.
Doral

United States, Florida
EMINAT Research (Site 1202), 2500 E. Commercial Blvd.
Fort Lauderdale

United States, Florida
Holy Cross Health (Site 1072), 4725 North Federal Highway
Fort Lauderdale

United States, Florida
North Florida / South Georgia Veterans Health System (Site 1133), 1601 SW Archer Rd.
Gainesville

United States, Florida
University of Florida (Site 1047), 1600 SW. Archer Rd.
Gainesville

United States, Florida
NW FL Clinical Research Group, LLC. (Site 1046), 400 Gulf Breeze Parkway
Gulf Breeze

United States, Florida
Indago Research and Health Center (Site 1050), 3700 W. 12th Ave., Ste. 300
Hialeah

United States, Florida
AGA Clinical Trials (Site 1026), 900 West 49th Street
Hialeah

United States, Florida
Community Research of South Florida (Site 1197), 7100 W. 20th Ave., Ste. 403
Hialeah

United States, Florida
New Generation Medical Research (Site 1204), 7600 W. 20th Ave., Ste. 106
Hialeah

United States, Florida
Best Quality Research, Inc. (Site 1237), 2387 W. 68th St., Ste. 403
Hialeah

United States, Florida
Innovative Health Medical Center (Site 1222), 6750 Taft Street
Hollywood

United States, Florida
University of Florida Jacksonville (Site 1039), 655 West 8th Street
Jacksonville

United States, Florida
Mayo Clinic Jacksonville (Site 1149), 4500 San Pablo Rd. S.
Jacksonville

United States, Florida
QC Trials (Site 1117), 300 W. 41st Street, Ste. 203
Miami Beach

United States, Florida
Lakes Research (Site 1037), 5801 NW 151 Street
Miami Lakes

United States, Florida
Savin Medical Group, LLC. (Site 1212), 5789B NW. 151st Street
Miami Lakes

United States, Florida
Amber Clinical Research, LLC. (Site 1206), 9000 NE. 2nd Avenue
Miami Shores

United States, Florida
Gonzalez MD & Aswad MD Health Services (Site 1238), 3401 NW. 7th Street
Miami

United States, Florida
Clintex Research Group, Inc. (Site 1231), 590 SW. 27th Ave.
Miami

United States, Florida
Advance Medical Research Center (Site 1193) 330 SW. 27th Ave., Ste. 701
Miami

United States, Florida
University of Miami Miller School of Medicine CoVID Unit (Site 1068), 1425 NW. 10th Ave.
Miami

United States, Florida
Florida International Medical Research (Site 1239), 1890 S. Red Rd., Ste. 103
Miami

United States, Florida
D&H National Research Centers (Site 1205), 8485 Bird Road
Miami

United States, Florida
Allied Biomedical Research Institute (Site 1227), 7100 SW. 47th St., Ste. 220
Miami

United States, Florida
Miami Clinical Research (Site 1089), 2400 SW. 69th Ave.
Miami

United States, Florida
Research Institute of South Florida, Inc. (Site 1201), 9835 SW. 72nd Street, Ste. 201
Miami

United States, Florida
RM Medical Research, Inc. (Site 1230), 10346 W. Flagler St.
Miami

United States, Florida
Pro Live Medical Research Corp (Site 1219), 12781 SW. 42nd Street
Miami

United States, Florida
Miami Dade Medical Research Institute, LLC (Site 1223), 8955 SW. 87th Ct.
Miami

United States, Florida
Bravo Health Care Center (Site 1221), 1440 79 Street
North Bay Village

United States, Florida
Orlando Immunology Center (Site 1045), 1707 North Mills Avenue
Orlando

United States, Florida
Clintheory (Site 1203), 7350 Sandlake Commons Blvd.
Orlando

United States, Florida
IMIC, Inc. (Site 1141), 18320 Franjo Rd
Palmetto Bay

United States, Florida
Family Clinical Trials (Site 1236), 1601 N. Palm Ave., Ste. 102
Pembroke Pines

United States, Florida
Physician Care Clinical Research, LLC. (Site 1242), 1617 S. Tuttle Ave., Ste. 1A
Sarasota

United States, Florida
Bassetti Medical Research, Inc. (Site 1158), 5825 US Highway 27 N.
Sebring

United States, Florida
DBC Research (Site 1188), 7707 N. University Dr., Ste. 106
Tamarac

United States, Florida
ETNA Medical Center (Site 1225), 7401 N. University Drive
Tamarac

United States, Florida
Moore Clinical Research, Inc. (Site 1164), 4257 W. Kennedy Blvd.
Tampa

United States, Florida
Tampa General Hospital Family Care Center Healthpark (Site 1088), 5802 N. 30th Street
Tampa

United States, Florida
Infectious Disease Consultants of the Treasure Coast (Site 1171), 3735 11th Cir., Ste. 201
Vero Beach

United States, Florida
AIDS Research and Treatment Center of the Treasure Coast (Site 1095), 981 37th Place
Vero Beach

United States, Florida
Triple O Research Institute PA (Site 1121), 2580 Metrocentre Blvd., Ste. 4
West Palm Beach

United States, Georgia
The Ponce de Leon Center (site 1015), 341 Ponce De Leon Avenue Northeast
Atlanta

United States, Georgia
Rare Disease Research, LLC. (Site 1248), 1891 Howell Mill Rd.NW, Ste. B
Atlanta

United States, Georgia
Agile Clinical Rsearch Trials, LLC (Site 1051), 750 Hammond Drive
Atlanta

United States, Georgia
Balanced Life Health Care Solutions/SKYCRNG (Site 1191), 2033 Buford Hwy., Ste. 109
Buford

United States, Georgia
IACT Health (Site 1035), 800 Talbotton Road
Columbus

United States, Georgia
Clintheory (Site 1254), 4300 Pleasant Hill Road
Duluth

United States, Georgia
One Health Research Clinic, Inc. (Site 1250), 5880 Live Oak Pkwy, Ste. 160
Norcross

United States, Georgia
Renew Health Clinical Research, LLC. (Site 1161), 1550 Janmar Rd.
Snellville

United States, Hawaii
John A. Burns School of Medicine UH Clinics at Kakaako (Site 1177), 651 Ilalo St.
Honolulu

United States, Idaho
Snake River Research, PLLC (Site 1120), 2900 Cortez Ave.
Idaho Falls

United States, Illinois
Metro Infectious Disease Consultants (Site 1106), 901 McClintock Dr., Ste. 201
Burr Ridge

United States, Illinois
Chicago Clinical Research Institute (Site 1132), 611 W. Roosevelt Rd.
Chicago

United States, Illinois
Northwestern University (Site 1025), 645 North Michigan Ave
Chicago

United States, Illinois
Rush University Medical Center (Site 1017), 600 Paulina St.
Chicago

United States, Illinois
University of Illinois at Chicago (Site 1147), 835 South Wood Street
Chicago

United States, Illinois
University of Chicago (Site 1064), 5841 S. Maryland Ave.
Chicago

United States, Illinois
Great Lakes Clinical Trials (Site 1049), 5149 N. Ashland Ave.
Chicago

United States, Indiana
Investigators Research Group, LLC. (Site 1170), 321 E. Northfield Dr., Ste. 100
Brownsburg

United States, Indiana
Roudebush VA Medical Center (Site 1217), 550 University Blvd
Indianapolis

United States, Kansas
University of Kansas Medical Center (Site 1042), 3901 Rainbow Boulevard
Kansas City

United States, Louisiana
MedPharmics (Site 1065), 3800 Houma Blvd.
Metairie

United States, Louisiana
Clinical Trials of America, LLC. (Site 1245) 3201 Armand Street
Monroe

United States, Louisiana
New Orleans Adolescent Trials Unit (Site 1028), 1440 Canal St., Suite 904
New Orleans

United States, Louisiana
Louisiana State University Health Sciences Center (Site 1153), 2000 Canal Street
New Orleans

United States, Louisiana
Ochsner Clinic Foundation (Site 1218), 1514 Jefferson Highway
New Orleans

United States, Maryland
Baltimore VA Medical Center (Site 1258), 10 N. Greene St.
Baltimore

United States, Maryland
Johns Hopkins University (Site 1006), 1830 East Monument Street
Baltimore

United States, Maryland
Walter Reed Army Institute of Research (Site 1118), 503 Robert Grant Ave.
Silver Spring

United States, Massachusetts
Massachusetts General Hospital (Site 1016), 55 Fruit Street
Boston

United States, Massachusetts
Beth Israel Deaconess Medical Center (Site 1166), 110 Francis Street
Boston

United States, Massachusetts
Brigham and Women's Hospital - Therapeutics Clinical Research Site (Site 1023), 75 Francis Street
Boston

United States, Massachusetts
University of Massachusetts Medical School (Site 1054), 55 Lake Avenue N.
Worcester

United States, Michigan
Vida Clinical Studies (Site 1244), 3815 Pelham Street
Dearborn

United States, Michigan
Revive Research Institute (Site 1257), 32255 Northwestern Hwy.
Farmington Hills

United States, Michigan
Revival Research Corporation (Site 1256), 13409 East 14 Mile Road
Sterling Heights

United States, Mississippi
Memorial Hospital at Gulfport (Site 1104), 4500 13th Street
Gulfport

United States, Mississippi
MedPharmics, LLC. (Site 1032), 15190 Community Rd.
Gulfport

United States, Missouri
University of Missouri Health Care System (Site 1224), 1 Hospital Drive
Columbia

United States, Missouri
Hannibal Clinic (Site 1129), 100 Medical Drive
Hannibal

United States, Missouri
Washington University School of Medicine (Site 1008), 620 South Taylor, Suite 200
Saint Louis

United States, Montana
Bozeman Health Deaconess Hospital (Site 1115), 931 Highland Blvd, Ste. 3103
Bozeman

United States, Montana
Mercury Street Medical Group (Site 1074), 300 W. Mercury St.
Butte

United States, Nebraska
Quality Clinical Research (Site 1112), 10040 Regency Circle
Omaha

United States, Nevada
Las Vegas Medical Research (Site 1048), 8530 W. Sunset Rd.
Las Vegas

United States, New Mexico
AXCES Research Group (Site 1152), 531 Harkle Road
Santa Fe

United States, New York
Bronx Prevention Research Center (Site 1108), 390 East 158th Street
Bronx

United States, New York
Lincoln Hospital (Site 1092), 249 East 149th Street
Bronx

United States, New York
Urban Health Plan, Inc. (Site 1243), 1065 Southern Blvd
Bronx

United States, New York
Jacobi Medical Center (Site 1105), 1400 Pelham Parkway South
Bronx

United States, New York
James J. Peters VA Medical Center (Site 1053), 130 West Kingsbridge Road
Bronx

United States, New York
Maimonides Medical Center (Site 1138), 4802 10th Avenue
Brooklyn

United States, New York
University at Buffalo, Emergency Medicine (Site 1172), 77 Goodell Street
Buffalo

United States, New York
Flushing Hospital Medical Center (Site 1067), 4500 Parsons Blvd
Flushing

United States, New York
Jamaica Hospital Medical Center (Site 1066), 8900 Van Wyck Expressway
Jamaica

United States, New York
Columbia Partnership for Prevention and Control of HIV/AIDS CTU (Site 1019), Columbia University Irving Medical Center, Department of Medicine - Division of Infectious Diseases, 180 Fort Washington Avenue, HP6 - Rm 604
New York

United States, New York
Cornell Clinical Trials Unit (Site 1011), NewYork-Presbyterian Hospital-Weill Cornell Medical Center, 525 East 68th Street
New York

United States, New York
Canton-Potsdam Hospital (Site 1076), 50 Leroy Street
Potsdam

United States, New York
University of Rochester (Site 1010), 601 Elmwood Ave
Rochester

United States, New York
SUNY Stony Brook NICHD (Site 1094), HSC L-02, Rm. 142 C
Stony Brook

United States, North Carolina
University of North Carolina at Chapel Hill (Site 1001), 130 Mason Farm Rd., Bioinformatics Bldg, 2nd Floor
Chapel Hill

United States, North Carolina
Carolina Clinical Research (Site 1167), 9040 Nations Ford Rd.
Charlotte

United States, North Carolina
Research Carolina Elite (Site 1247), 7480 Waterside Loop Road, Suite 201
Denver

United States, North Carolina
Duke University Medical Center (Site 1041), 40 Duke Medicine Circle
Durham

United States, North Carolina
Carteret Medical Group, LLC. (Site 1249), 302 Medical Park Ct.
Morehead City

United States, North Carolina
Wake Forest University Health Sciences (Site 1038), 1 Medical Center Boulevard
Winston-Salem

United States, North Dakota
Sanford Health (Site 1084), 801 Broadway N.
Fargo

United States, Ohio
The Christ Hospital (Site 1119), 2123 Auburn Avenue
Cincinnati

United States, Ohio
Case Western Reserve University (Site 1033), 2061 Cornell Road
Cleveland

United States, Ohio
MetroHealth Medical Center (Site 1195), 2500 Metrohealth Dr.
Cleveland

United States, Ohio
Ohio State University Medical Center (Site 1020), 480 Medical Center Drive
Columbus

United States, Ohio
Cincinnati CRS (Site 1004), University of Cincinnati, University Hospital, 200 Albert Sabin Way
Ohio City

United States, Ohio
STAT Research (Site 1107), 66 Remick Blvd.
Springboro

United States, Oklahoma
Ascension St. John Clinical Research Institute (Site 1090), 1725 East 19th Street
Tulsa

United States, Oregon
Providence Portland Medical Center (Site 1098), 4805 NE. Glisan Street
Portland

United States, Oregon
Kaiser Permanente Center for Health Research (Site 1079), 3800 N. Interstate Ave.
Portland

United States, Oregon
Portland VA Medical Center (Site 1131), 3710 SW US Veterans Hospital Rd.
Portland

United States, Oregon
Oregon Health and Science University (Site 1259), 3181 SW. 10th Avenue
Portland

United States, Pennsylvania
Doylestown Hospital (Site 1122), 595 W. State Street
Doylestown

United States, Pennsylvania
University of Pennsylvania (Site 1031), 3400 Spruce Street
Philadelphia

United States, Pennsylvania
The University of Pittsburgh (Site 1018), 3471 5th Ave.
Pittsburgh

United States, Pennsylvania
Veterans Affairs Pittsburgh Healthcare System (Site 1070), University Drive C.
Pittsburgh

United States, Rhode Island
The Miriam Hospital Clinical Research Site (1142), 164 Summit Avenue
Providence

United States, South Carolina
Medtrial, LLC (Site 1134), 1718 Saint Julian Pl., Ste. 2
Columbia

United States, South Carolina
Clinovacare Medical Clinical Research Center (Site 1211), 160 Medical Circle Suite D
West Columbia

United States, South Dakota
American Indian Clinical Trials Research Network (Site 1148), 717 Meade Street
Rapid City

United States, South Dakota
Sanford USD Medical Center (Site 1078), 1305 W. 18th St.
Sioux Falls

United States, Tennessee
Clinical Trials Center of Middle Tennessee (Site 1183), 100 Covey Drive
Franklin

United States, Tennessee
Vanderbilt Therapeutics Clinical Research (Site 1013), Vanderbilt Health One Hundred Oaks, 719 Thompson Ln., Ste 47183
Nashville

United States, Texas
Saint Hope Foundation Inc. (Site 1100), 6800 West Loop Street, Ste. 560
Bellaire

United States, Texas
South Texas Medical Research Institute, Inc./TTS Research (Site 1198), 1420 River Road
Boerne

United States, Texas
PanAmerican Clinical Research, LLC. (Site 1069), 1416 Palm Blvd.
Brownsville

United States, Texas
Trinity Health and Wellness Center (Site 1030), 219 Sunset Avenue
Dallas

United States, Texas
UT Southwestern HIV/ID Clinical Trials Unit (Site 1208), 1936 Amelia Court
Dallas

United States, Texas
Doctors Hospital at Renaissance Health Institute for Research and Development (Site 1145), 5323 S. McColl Rd.
Edinburg

United States, Texas
Sealy Institute for Vaccine Sciences Clincial Trials Program (Site 1044), 400 Harborside Drive
Galveston

United States, Texas
Rheumatology Center of Houston (Site 1252), 1200 Binz St., Ste. 1495
Houston

United States, Texas
Lyndon B. Johnson Hospital (Site 1014), 5656 Kelley Street
Houston

United States, Texas
University of Texas Health Science Center at Houston (Site 1055), 6431 Fannin Street, Ste. 2.112
Houston

United States, Texas
Houston Methodist Hospital (Site 1123), 6565 Fannin Street
Houston

United States, Texas
Dynamic Medical Research Group (Site 1081), 8314 Southwest Fwy
Houston

United States, Texas
Fairway Medical Clinic (Site 1156), 4910 Telephone Road
Houston

United States, Texas
Houston Heart and Vascular Associates (Site 1215), 1485 FM 1960 Bypass R. E., Ste. 100
Humble

United States, Texas
SMS Clincial Research, LLC. (Site 1060), 1210 N. Galloway Ave.
Mesquite

United States, Texas
Epic Medical Research, LLC (Site 1233), 106 Plaza Drive
Red Oak

United States, Texas
San Antonio Military Medical Center (Site 1173), 3551 Roger Brooke Dr.
San Antonio

United States, Virginia
Inova Fairfax Medical Campus (Site 1029), 3300 Gallows Road
Falls Church

United States, Virginia
Clinical Research Partners LLC (Site 1196), 7110 Forest Ave., Ste. 201
Richmond

United States, Washington
EvergreenHealth (Site 1080), 12040 NE 128th Street, Ste MS-77
Kirkland

United States, Washington
University of Washington ACTU (Site 1012), Harborview Medical Center, 325 9th Ave.
Seattle

United States, Washington
Providence Medical Research Center (Site 1075), 105 W. 8th Ave., Ste. 6050W
Spokane

United States, West Virginia
Hershel Woody Williams VA Medical Center (Site 1128), 1540 Spring Valley Drive
Huntington

United States, West Virginia
West VA University, Mary Babb Randolph Cancer Center (Site 1178), 1 Medical Center Drive
Morgantown

United States, Wisconsin
Vida Clinical Studies (Site 1246), 5757 West Oklahoma Avenue
Milwaukee

United States, Wisconsin
Medical College of Wisconsin, Inc. (Site 1036), 8701 Watertown Plank Road
Milwaukee

United States, Wisconsin
Allegiance Research Specialists (Site 1162), 2645 N. Mayfair Rd., Ste. 200
Wauwatosa

Argentina, Buenos Aires
Instituto Médico Platense (Site 3011), Avenida 51 335
La Plata

Argentina, Ciudad Autónoma De Buenos Aires
Fundación Sanatorio Güemes (Site 3001), Francisco Acuña de Figueroa 1240
Buenos Aires

Argentina, Córdoba
Instituto Médico Río Cuarto (Site 3005), Hipólito Yrigoyen 1020
Río Cuarto

Argentina, Santa Fe
Instituto Médico de la Fundación Estudios Clínicos (Site 3009), Italia 428
Rosario

Argentina
Clínica Adventista Belgrano (Site 3007), Estomba 1710
Ciudad Autonoma de Buenos Aires

Argentina
Instituto Ave Pulmo (Site 3006), Carlos M. Alvear 3345
Mar Del Plata

Argentina
Hospital Universitario Austral (Site 3004), Av. Juan Domingo Peron, Derqui
Pilar

Brazil, Distrito Federal
L2 Ip - Instituto de Pesquisas Clinicas Ltda (Site 4008), SGAS 613, Conjunto E, Lote 95, Sala 6
Brasília

Brazil, Minas Gerais
Hospital Das Clinicas Da Universidade Federal de Minas Gerais (Site 4001), Avenida Alfredo Balena 190
Belo Horizonte

Brazil, Minas Gerais
SOM Federal University Minas Gerais Brazil (Site 4002), Avenida Alfredo Balena 190
Belo Horizonte

Brazil, Rio Grande Do Sul
Hospital Nossa Senhora da Conceicao (Site 4004), Avenida Francisco Trein 596
Porto Alegre

Brazil, Santa Catarina
Hospital Dia do Pulmão (Site 4007), Rua Engenheiro Paul Werner, 1141
Blumenau

Brazil, São Paulo
Hospital Das Clinicas da Faculdade de Medicina de Ribeirão Preto (Site 4003), Avenida Bandeirantes 3900, Campus Universitário
Ribeirão Preto

Brazil
Instituto de Pesquisa Clínica Evandro Chagas (Site 4005), Avenida Brasil, 4365
Rio De Janeiro

Brazil
Hospital E Maternidade Celso Pierro (Site 4006), Avenue John Boyd Dunlop S/n
São Paulo

Canada, British Columbia
Medical Arts Health Research Group (Site 2003), 360-1855 Kirschner Rd.
Kelowna

Canada, British Columbia
Vancouver ID Research and Care Centre Society (Site 2006), Infectious Disease Clinic Downtown
Vancouver

Canada, Ontario
Dr. Anil K. Gupta Medicine Professional Corporation (Site 2004), 1620 Albion Rd., Suite 106
Toronto

Costa Rica, San José
Clinica San Agustin Research (Site 9601), Meters West from the National Bank
Desamparados

Costa Rica
Corporacion GIHEMA SA (Site 9602), Carretera Prospero Fernandez
Escazú

Guatemala
Centro Medico Militar (Site 9401), Finca El Palomar, Acatan, Sta. Rosita Zona 16
Ciudad De Guatemala

Mexico, Coahuila
CIMAB SA de CV (Site 6002), Francisco I Madero 270 Sur
Torreon

Mexico, Distrito Federal
Oaxaca Site Management Organization (Site 6004), Calle Humboldt 302, Colonia Centro
Oaxaca

Mexico, Jalisco
Centro de Investigación Farmacéutica Especializada de Occidente (Site 6006), Av. Vallarta 1670, Piso 2 PH1, Colonia Americana
Guadalajara

Mexico, Yucatán
Kohler and Milstein Research (Site 6013), Avenida Colón 197, García Ginerés
Mérida

Philippines, Cavite
De La Salle Health Sciences Institute (Site 9504), Gov. Mangubat Avenue
Cavite City

Philippines, National Capital Region
Makati Medical Center (Site 9502), No. 2 Amorsolo Street, Legaspi Village
Makati City

Philippines, National Capital Region
Asian Hospital and Medical Center (Site 9503), 2205 Civic Drive
Muntinlupa

Puerto Rico
Puerto Rico AIDS Clinical Trials Unit (Site 1024), Proyecto ACTU Biomedical Building II
San Juan

South Africa, Ekurhuleni, Gauteng
Peermed Clinical Trial Center (Site 9215), Corner of Voortrekker and Monument Roads
Kempton Park

South Africa, Gauteng
Worthwhile Clinical Trials (Site 9214), No. 1 Mowbray Avenue
Benoni

South Africa, Gauteng
The Aurum Institute Tembisa Clinical Research Site (Site 9217), Cnr Flint Mazibuko / Rev RTJ Namane Drive
Johannesburg

South Africa, Gauteng
Roodepoort Medicross (Site 9220), 54 Ontdekkers Road
Johannesburg

South Africa, Gauteng
Soweto ACTG CRS (Site 9203), Chris Hani Road
Johannesburg

South Africa, Gauteng
Helen Joseph Hospital (Site 9201), Perth Road
Johannesburg

South Africa, Gauteng
Setshaba Research Centre (Site 9205), 2088 Block H
Pretoria

South Africa, Gauteng
Into Research (Site 9210), Totius Street
Tshwane

South Africa, Kwazulu - Natal
Durban International Clinical Research Site (Site 9208), Sidmouth Avenue
Durban

South Africa, Matjhabeng, Free State
Welkom Clinical Trial Centre (Site 9211), 189 Power Road
Welkom

South Africa, North-West
The Aurum Institute Klerksdorp Clinical Research Center (Site 9204), Corner Margaretha Prinsloo St. and O.R. Tambo St.
Klerksdorp

South Africa, North-West
The Aurum Institute Rustenburg Clinical Research Site (Site 9202), 50 Steen St., c/o Pretorius St.
Rustenburg

South Africa
TASK Eden (Site 9218), G, 4 Victoria St.
George

South Africa
CLINRESCO, ARWYP Medical Suites (Site 9209), 22 Pine Avenue
Johannesburg

South Africa
Mzansi Ethical Research Centre (Site 9212), 184 Cowen Ntuli Street, Steve Tschwete
Mpumalanga

South Africa
Global Clinical Trials Sunnyside (Site 9216), 175 Steve Biko Street
Pretoria

Sponsors and Collaborators

National Institute of Allergy and Infectious Diseases (NIAID)

Eli Lilly and Company

AIDS Clinical Trials Group

Brii Biosciences Limited

AstraZeneca

Sagent Pharmaceuticals

Synairgen Research Ltd.

Bristol-Myers Squibb

SAb Biotherapeutics, Inc.

Investigators

Study Chair: David Smith, MD, MAS University of California, San Diego

More Information